Neuroectodermal Tumors: Clinical Trials

19 trials for Neuroectodermal Tumors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 suspended. 19 Phase 2, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 219Suspended 19
Phase 17Suspended 7

Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases
Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Phase 1 / Phase 2SuspendedMayo Clinic232026-11-302026-10-20
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma
Phase 1 / Phase 2SuspendedWashington University School of Medicine682026-11-302026-10-30
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma
Phase 2SuspendedNational Cancer Institute (NCI)1842024-11-082026-11-12
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS System, Lumason, Bevacizumab - Glioblastoma Multiforme, Glioblastoma
Phase 1 / Phase 2SuspendedNaviFUS Corporation102024-10-222026-09-09
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
T3011 + Cobimetinib - Melanoma, Malignant Melanoma
Phase 2SuspendedImmVira Pharma Co. Ltd682024-06-302024-02-01
Methimazole in Patients With Progressive Glioblastoma
Methimazole, Recurrent Glioblastoma Surgical Resection, Pharmacodynamic Assays - Glioblastoma, Glioma
Phase 2SuspendedCase Comprehensive Cancer Center192023-01-302026-11-17
A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS) - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
Phase 2SuspendedSonALAsense, Inc.152022-08-122024-09-19
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
XmAb20717 - Microsatellite High Cancers, Peritoneal Mesothelioma
Phase 2SuspendedM.D. Anderson Cancer Center1402022-08-052026-10-13
Neoadjuvant T-VEC in High Risk Early Melanoma
T-Vec - Melanoma
Phase 2SuspendedUniversity of California, Davis62020-05-212023-09-15
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Laboratory Biomarker Analysis, Pembrolizumab, Propranolol Hydrochloride - Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Phase 1 / Phase 2SuspendedRoswell Park Cancer Institute472018-01-312026-07-15
Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Propranolol hydrochloride, Placebo pill - Stages III Skin Melanoma, Stages II Skin Melanoma
Phase 2SuspendedUniversity Hospital, Geneva4502016-06-012019-05-10
A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
Antineoplaston therapy (Atengenal + Astugenal) - Diffuse, Intrinsic Pontine Glioma
Phase 2SuspendedBurzynski Research Institute12016-04-132025-09-16
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
[177]Lu-DOTA-TATE - Carcinoma, Neuroendocrine
Phase 2SuspendedAHS Cancer Control Alberta4132014-04-292026-07-27
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
TPI 287, Bevacizumab - Glioblastoma Multiforme
Phase 1 / Phase 2SuspendedCortice Biosciences, Inc.922013-08-012023-02-22
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
Bevacizumab and Carboplatin - Glioblastoma Multiforme, Anaplastic Astrocytoma
Phase 1 / Phase 2SuspendedNorthwell Health542011-09-012026-06-01
Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
sargramostim, paclitaxel - Melanoma (Skin)
Phase 2SuspendedUniversity of Virginia422005-07-012013-12-10
Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma
autologous dexosomes loaded with tumor-specific peptides - Melanoma
Phase 2SuspendedAnosys602002-07-012005-06-24
Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2
M40403 - IL-2 Induced Hypotension
Phase 1 / Phase 2SuspendedMetaPhore Pharmaceuticals482001-12-012005-06-24
Biological Therapy in Treating Patients With Primary or Advanced Glioma
aldesleukin, lymphokine-activated killer cells - Brain and Central Nervous System Tumors
Phase 2SuspendedWeill Medical College of Cornell University1997-07-012009-02-09

Narrower conditions

Melanoma (8)  ·  Glioblastoma (6)  ·  Brain Neoplasms (3)  ·  Diffuse Intrinsic Pontine Glioma (3)  ·  Glioma (3)  ·  Astrocytoma (2)  ·  Carcinoma, Neuroendocrine (2)  ·  Neoplasms (2)  ·  Recurrence (2)  ·  Carcinoma, Renal Cell (1)  ·  Central Nervous System Neoplasms (1)  ·  Ependymoma (1)  ·  Gliosarcoma (1)  ·  Hodgkin Disease (1)  ·  Hypotension (1)

Broader conditions

Neoplasms by Histologic Type (19)  ·  Neoplasms, Germ Cell and Embryonal (19)  ·  Neoplasms, Nerve Tissue (18)  ·  Neoplasms (17)  ·  Neoplasms by Site (14)  ·  Neoplasms, Glandular and Epithelial (12)  ·  Neuroendocrine Tumors (10)  ·  Neoplasms, Neuroepithelial (9)  ·  Nevi and Melanomas (8)  ·  Skin Diseases (8)  ·  Skin Neoplasms (8)  ·  Skin and Connective Tissue Diseases (8)  ·  Brain Diseases (6)  ·  Central Nervous System Diseases (6)

Interventions

Bevacizumab (3)  ·  Biopsy (2)  ·  Immunoglobulin G (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  Nivolumab (2)  ·  Propranolol (2)  ·  Specimen Handling (2)  ·  pembrolizumab (2)  ·  CA-4948 (1)  ·  Carboplatin (1)  ·  Disulfides (1)  ·  Lomustine (1)  ·  Methimazole (1)  ·  Paclitaxel (1)  ·  Radiosurgery (1)

Sponsors

AHS Cancer Control Alberta (1)  ·  Anosys (1)  ·  Burzynski Research Institute (1)  ·  Case Comprehensive Cancer Center (1)  ·  Cortice Biosciences, Inc. (1)  ·  ImmVira Pharma Co. Ltd (1)  ·  M.D. Anderson Cancer Center (1)  ·  Mayo Clinic (1)  ·  MetaPhore Pharmaceuticals (1)  ·  National Cancer Institute (NCI) (1)  ·  NaviFUS Corporation (1)  ·  Northwell Health (1)  ·  Roswell Park Cancer Institute (1)  ·  SonALAsense, Inc. (1)  ·  University Hospital, Geneva (1)

Countries

United States (16)  ·  Canada (1)  ·  Switzerland (1)

Top investigators

Arvind Nageshwara Dasaru, MD (1)  ·  Bently Doonan, MD, MS (1)  ·  Cameron Gaskill, MD (1)  ·  Corina Andresen, MD (1)  ·  David Peereboom, MD (1)  ·  Eric M Thompson, M.D. (1)  ·  J. P. Duic, M.D. (1)  ·  Jian Campian, M.D. (1)  ·  John Boockvar, MD (1)  ·  Louis B. Nabors, III, M.D. (1)  ·  Michael C Lowe, MD (1)  ·  Michael Lim (1)  ·  Nimish Mohile, M.D. (1)  ·  Pierre Giglio, M.D. (1)

Results publications

PMID 8625188

NIH funding

R01CA296813 (1), R44CA261516 (1), U10CA180821 (1)